Bemarituzumab + Flot regimen
Phase 2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas
Conditions
Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas, Overexpression FGFR2b
Trial Timeline
Jan 1, 2026 → Jan 1, 2026
NCT ID
NCT06967987About Bemarituzumab + Flot regimen
Bemarituzumab + Flot regimen is a phase 2 stage product being developed by Amgen for Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06967987. Target conditions include Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas, Overexpression FGFR2b.
What happened to similar drugs?
5 of 20 similar drugs in Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas were approved
Approved (5) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06967987 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas